Stock GSK GSK PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings GSK plc Nyse

Equities

GSK

US37733W2044

Market Closed - Nyse
Other stock markets
 01:30:03 29/06/2024 am IST 		5-day change 1st Jan Change
38.5 USD -0.36% Intraday chart for GSK plc -4.89% +3.89%
28/06 GSK reaches settlement over Zantac case in Illinois AN
28/06 GSK Reaches Settlement in Illinois Zantac Lawsuit DJ

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • With a P/E ratio at 11.46 for the current year and 9.67 for next year, earnings multiples are highly attractive compared with competitors.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company appears highly valued given the size of its balance sheet.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
GSK PLC Stock GSK plc
+3.89% 78.69B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 819B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 351B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 329B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.68% 298B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.04% 225B
A+
NOVARTIS AG Stock Novartis AG
+13.31% 217B
B-
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
C+
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 158B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. GSK Stock
  5. Ratings GSK plc